Shuiping Gao

784 total citations
28 papers, 539 citations indexed

About

Shuiping Gao is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Shuiping Gao has authored 28 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Molecular Biology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Shuiping Gao's work include HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Cancer Treatment and Pharmacology (3 papers). Shuiping Gao is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Cancer Treatment and Pharmacology (3 papers). Shuiping Gao collaborates with scholars based in China, United States and South Korea. Shuiping Gao's co-authors include Hefen Sun, Liangdong Li, Wei Jin, Yang Zhao, Honglin Jiang, Wenyan Fu, Lipeng Yang, Xin Hu, Min‐Te Chen and Honglin Jiang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Shuiping Gao

26 papers receiving 531 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shuiping Gao China 13 263 229 194 99 74 28 539
Monica Milano Italy 10 134 0.5× 311 1.4× 176 0.9× 138 1.4× 83 1.1× 22 489
Gillian Bethune Canada 8 189 0.7× 222 1.0× 119 0.6× 149 1.5× 86 1.2× 18 483
Sean E. Sissons United States 8 242 0.9× 201 0.9× 145 0.7× 75 0.8× 29 0.4× 11 476
Ning Liao China 13 197 0.7× 191 0.8× 205 1.1× 110 1.1× 37 0.5× 48 449
Sarah Croessmann United States 13 217 0.8× 219 1.0× 239 1.2× 136 1.4× 35 0.5× 26 492
Santai Song China 14 227 0.9× 340 1.5× 150 0.8× 157 1.6× 33 0.4× 65 608
Elisa De Camilli Italy 14 156 0.6× 133 0.6× 126 0.6× 86 0.9× 53 0.7× 27 447
Jessica Young United States 12 243 0.9× 270 1.2× 331 1.7× 159 1.6× 106 1.4× 29 652
Huan Cheng China 16 306 1.2× 256 1.1× 130 0.7× 53 0.5× 70 0.9× 26 561
Xiying Shao China 11 172 0.7× 184 0.8× 189 1.0× 85 0.9× 31 0.4× 60 462

Countries citing papers authored by Shuiping Gao

Since Specialization
Citations

This map shows the geographic impact of Shuiping Gao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuiping Gao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuiping Gao more than expected).

Fields of papers citing papers by Shuiping Gao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuiping Gao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuiping Gao. The network helps show where Shuiping Gao may publish in the future.

Co-authorship network of co-authors of Shuiping Gao

This figure shows the co-authorship network connecting the top 25 collaborators of Shuiping Gao. A scholar is included among the top collaborators of Shuiping Gao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuiping Gao. Shuiping Gao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Park, Wungki, Jian Zhang, Farshid Dayyani, et al.. (2024). Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3002–3002. 5 indexed citations
4.
5.
Zhang, Jian, Rujiao Liu, Shuiping Gao, et al.. (2024). 9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study.. Journal of Clinical Oncology. 42(16_suppl). 3013–3013. 6 indexed citations
6.
Liu, Rujiao, Xichun Hu, Jian Zhang, et al.. (2024). IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: A phase I dose-escalation study.. Journal of Clinical Oncology. 42(16_suppl). e14506–e14506. 2 indexed citations
7.
Tolcher, Anthony W., Xiaohua Wu, Jian Zhang, et al.. (2023). A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 2531–2531. 5 indexed citations
8.
Zhang, Jian, Rujiao Liu, Shuiping Gao, et al.. (2023). Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours. npj Breast Cancer. 9(1). 28–28. 36 indexed citations
9.
Zhang, Jian, Rujiao Liu, Shuiping Gao, et al.. (2023). BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer (MBC): Results from a phase I study.. Journal of Clinical Oncology. 41(16_suppl). e13051–e13051. 2 indexed citations
10.
Cheng, Xiangdong, Zhengbo Song, Jian Zhang, et al.. (2023). Preliminary results of a phase I dose escalation study of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced tumors.. Journal of Clinical Oncology. 41(16_suppl). 2535–2535. 3 indexed citations
11.
Hu, Xichun, Jian Zhang, Rujiao Liu, et al.. (2022). Updated results and biomarker analyses from the phase I trial of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 1037–1037. 6 indexed citations
12.
Hu, Xichun, Jian Zhang, Rujiao Liu, et al.. (2021). Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 1024–1024. 20 indexed citations
13.
Liu, Rujiao, Wenhua Li, Yanchun Meng, et al.. (2021). Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors. Therapeutic Advances in Medical Oncology. 13. 4277432560–4277432560. 9 indexed citations
14.
Chen, Min‐Te, Hefen Sun, Yang Zhao, et al.. (2017). Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis. Scientific Reports. 7(1). 9254–9254. 133 indexed citations
15.
Gao, Shuiping, Hefen Sun, Wenyan Fu, et al.. (2017). High expression of COX5B is associated with poor prognosis in breast cancer. Future Oncology. 13(19). 1711–1719. 13 indexed citations
16.
Li, Liangdong, Hefen Sun, Shuiping Gao, et al.. (2015). Down-Regulation of NDUFB9 Promotes Breast Cancer Cell Proliferation, Metastasis by Mediating Mitochondrial Metabolism. PLoS ONE. 10(12). e0144441–e0144441. 58 indexed citations
17.
Gao, Shuiping, Hefen Sun, Honglin Jiang, et al.. (2015). Loss of TIM50 suppresses proliferation and induces apoptosis in breast cancer. Tumor Biology. 37(1). 1279–1287. 20 indexed citations
18.
Jiang, Honglin, Hefen Sun, Shuiping Gao, et al.. (2015). Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling. Oncotarget. 6(18). 16352–16365. 40 indexed citations
19.
Wang, Qiaoqiao, Jiyu Li, Hefen Sun, et al.. (2013). Nrf2 is associated with the regulation of basal transcription activity of the <italic>BRCA1</italic> gene. Acta Biochimica et Biophysica Sinica. 45(3). 179–187. 25 indexed citations
20.
Gao, Shuiping, et al.. (2010). Cloning of a flower-specific expression promoter from Arabidopsis thaliana and its plant expression vector construction. Forestry Studies in China. 12(4). 201–205. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Monica Milano Breakdown of academic impact, for papers by Gillian Bethune Breakdown of academic impact, for papers by Sean E. Sissons Breakdown of academic impact, for papers by Ning Liao Breakdown of academic impact, for papers by Sarah Croessmann Breakdown of academic impact, for papers by Santai Song Breakdown of academic impact, for papers by Elisa De Camilli Breakdown of academic impact, for papers by Jessica Young Breakdown of academic impact, for papers by Huan Cheng Breakdown of academic impact, for papers by Xiying Shao
Rankless by CCL
2026